查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1888714

美國骨關節炎治療市場規模、佔有率和趨勢分析報告：按產品、應用、主要用戶和細分市場預測（2025-2033 年）

U.S. Osteoarthritis Therapeutics Market Size, Share & Trends Analysis Report By Product (Viscosupplements, Platelet-Rich Plasma Therapy, Adipose Tissue Therapy, Bone Graft Substitutes), By Application, By Primary User, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 190 Pages | 商品交期: 2-10個工作天內

價格

美國骨關節炎治療市場摘要

據估計，2024年美國骨關節炎治療市場規模為21.5億美元，預計2033年將達45億美元。

預計 2025 年至 2033 年的複合年成長率將達到 8.61%。人口老化加劇、肥胖和關節損傷的盛行率上升，以及對微創治療和再生醫學的需求不斷成長，正在推動骨關節炎治療產業的發展。

人口老化是市場成長的主要驅動力。根據美國疾病管制與預防中心（CDC）的數據，截至2024年2月，美國18歲及以上美國的年齡調整後關節炎盛行率為18.9%，而75歲及以上成年人的盛行率則高達53.9%。隨著美國美國老化，針對老年人的骨關節炎治療需求日益成長，尤其是在預計2030年老年人口將佔總人口約20%的情況下。 2024年9月，CDC報告稱，2021年8月至2023年8月期間，40.3%的美國成年人被歸類為肥胖。肥胖是骨關節炎的重要危險因素，尤其是在負重關節，其高盛行率導致骨關節炎病例數量不斷增加。

此外，與運動和工傷事故相關的關節損傷日益增多，也加速了骨關節炎的發展。隨著越來越多人參與體育活動，他們的關節損傷以及隨後發展為骨關節炎的風險也隨之增加。 2024年2月，國際勞工組織（ILO）估計，全球每年約有3.95億工人遭受非致命性工傷，其中許多會導致關節損傷。這提高了人們對關節健康管理必要性的認知，也促使美國對骨關節炎治療的需求不斷成長。

最後，微創和再生醫學的興起正在對美國骨關節炎治療市場產生關鍵影響。人們對非手術治療方法，例如透明質酸注射、富血小板血漿（PRP）療法和幹細胞療法，越來越感興趣，因為與傳統手術治療相比，這些療法具有恢復期短、副作用少等優勢，是更有效的替代方案。預計這種治療方法偏好的轉變將在未來幾年繼續推動市場成長。

人口老化、肥胖率上升、關節損傷增加以及人們對微創和再生醫學日益成長的需求，是推動該產業發展的主要因素。預計這些因素將支撐市場的持續成長，而治療技術的進步將在滿足老齡化社會的需求方面發揮關鍵作用。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章美國骨關節炎治療市場變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章美國骨關節炎治療市場：按產品分類的業務分析

  • 按產品分類的市場佔有率（2024 年和 2033 年）
  • 按產品分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 黏彈性補充劑
  • 富血小板血漿（PRP）療法
  • 骨移植替代物
  • 骨髓抽吸濃縮液（BMAC）療法
  • 脂肪組織療法
  • 自體軟骨細胞移植術（ACI），包括MACI
  • 幹細胞（其他）
  • 其他

第5章美國骨關節炎治療市場：按應用領域分類的業務分析

  • 按應用領域分類的市場佔有率（2024 年和 2033 年）
  • 按應用領域分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 膝骨關節炎
  • 髖關節骨關節炎
  • 肩關節骨關節炎
  • 脊椎骨關節炎
  • 踝關節和足部骨關節炎
  • 其他

第6章美國骨關節炎治療市場：主要用戶業務分析

  • 主要用戶市場佔有率（2024 年和 2033 年）
  • 主要用戶市場規模、預測與趨勢分析（2021-2033）
  • 骨科醫生
  • 風濕症醫師
  • 運動醫學專家
  • 再生醫學專家
  • 其他

第7章 競爭情勢

  • 參與企業概況
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/列表
    • Stryker
    • Zimmer Biomet Holdings, Inc.
    • Medtronic
    • Anika Therapeutics, Inc.
    • Bioventus
    • Vericel Corporation
    • Smith &Nephew
    • Fidia Farmaceutici SpA
    • Seikagaku Corporation
    • Sanofi
Product Code: GVR-4-68040-817-6

U.S. Osteoarthritis Therapeutics Market Summary

The U.S. osteoarthritis therapeutics market size was estimated at USD 2.15 billion in 2024 and is projected to reach USD 4.50 billion by 2033, growing at a CAGR of 8.61% from 2025 to 2033. Growing geriatric population, rising prevalence of obesity and joint injuries, and increasing demand for minimally invasive and regenerative therapies are driving the osteoarthritis therapeutics industry.

The aging population is a major factor driving the growth of the market. According to the Centers for Disease Control and Prevention (CDC), in February 2024, the age-adjusted prevalence of arthritis among U.S. adults aged 18 and older was 18.9%, with the prevalence in adults aged 75 and older reaching 53.9%. As the U.S. population ages, particularly with the elderly demographic projected to represent nearly 20% of the population by 2030, the demand for osteoarthritis treatments tailored to the older age group is increasing. In September 2024, the CDC reported that 40.3% of U.S. adults were classified as obese between August 2021 and August 2023. Obesity is a significant risk factor for osteoarthritis, especially in weight-bearing joints, and its high prevalence is contributing to the rising number of osteoarthritis cases.

Additionally, the increase in joint injuries, particularly those related to sports and work-related accidents, is accelerating the onset of osteoarthritis. As more individuals engage in physical activities, the likelihood of joint damage and subsequent osteoarthritis increases. In February 2024, the International Labour Organization (ILO) estimated that approximately 395 million workers worldwide sustain non-fatal work injuries annually, many of which result in joint damage. This has increased awareness of the need for joint health management and has contributed to the rising demand for osteoarthritis therapeutics in the U.S.

Finally, the shift toward minimally invasive and regenerative therapies is playing a significant role in shaping the U.S. osteoarthritis therapeutics market. There is growing interest in non-surgical treatments, such as hyaluronic acid injections, platelet-rich plasma (PRP) therapy, and stem cell therapies, as they offer effective alternatives with shorter recovery times and fewer side effects compared to traditional surgical options. This shift in treatment preferences is expected to continue fueling market growth in the coming years.

The industry is driven by the aging population, rising obesity rates, increasing joint injuries, and a growing preference for minimally invasive and regenerative therapies. These factors are expected to support continued market growth, with advancements in treatment technologies playing a key role in meeting the demands of an aging population.

U.S. Osteoarthritis Therapeutics Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. osteoarthritis therapeutics market report based on product, application, and primary user:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Viscosupplements
  • Platelet-Rich Plasma (PRP) Therapy
  • Bone Graft Substitutes
  • BMAC (Bone Marrow Aspirate Concentrate) Therapy
  • Adipose Tissue Therapy
  • Autologous Chondrocyte Implantation (ACI), Including MACI
  • Stem Cell (other)
  • Other (Cartilage Resurfacing Products)
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Knee Osteoarthritis
  • Hip Osteoarthritis
  • Shoulder Osteoarthritis
  • Spine Osteoarthritis
  • Ankle & Foot Osteoarthritis
  • Other
  • Primary User Outlook (Revenue, USD Million, 2021 - 2033)
  • Orthopedic Surgeons
  • Rheumatologists
  • Sports Medicine Specialists
  • Regenerative Medicine Specialists
  • Other

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Primary User
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Osteoarthritis Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. U.S. Osteoarthritis Therapeutics Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2033
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Viscosupplements
    • 4.4.1. Viscosupplements Market, 2021 - 2033 (USD Million)
  • 4.5. Platelet-Rich Plasma (PRP) Therapy
    • 4.5.1. Platelet-Rich Plasma (PRP) Therapy Market, 2021 - 2033 (USD Million)
  • 4.6. Bone Graft Substitutes
    • 4.6.1. Bone Graft Substitutes Market, 2021 - 2033 (USD Million)
  • 4.7. BMAC (Bone Marrow Aspirate Concentrate) Therapy
    • 4.7.1. BMAC (Bone Marrow Aspirate Concentrate) Therapy Market, 2021 - 2033 (USD Million)
  • 4.8. Adipose Tissue Therapy
    • 4.8.1. Adipose Tissue Therapy Market, 2021 - 2033 (USD Million)
  • 4.9. Autologous Chondrocyte Implantation (ACI), Including MACI
    • 4.9.1. Autologous Chondrocyte Implantation (ACI), Including MACI Market, 2021 - 2033 (USD Million)
  • 4.10. Stem Cell (other)
    • 4.10.1. Stem Cell (other) Market, 2021 - 2033 (USD Million)
  • 4.11. Others
    • 4.11.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Osteoarthritis Therapeutics Market: Application Business Analysis

  • 5.1. Application Market Share, 2024 & 2033
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by application, 2021 to 2033 (USD Million)
  • 5.4. Knee Osteoarthritis
    • 5.4.1. Knee Osteoarthritis Market, 2021 - 2033 (USD Million)
  • 5.5. Hip Osteoarthritis
    • 5.5.1. Hip Osteoarthritis Market, 2021 - 2033 (USD Million)
  • 5.6. Shoulder Osteoarthritis
    • 5.6.1. Shoulder Osteoarthritis Market, 2021 - 2033 (USD Million)
  • 5.7. Spine Osteoarthritis
    • 5.7.1. Spine Osteoarthritis Market, 2021 - 2033 (USD Million)
  • 5.8. Ankle & Foot Osteoarthritis
    • 5.8.1. Ankle & Foot Osteoarthritis Market, 2021 - 2033 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. U.S. Osteoarthritis Therapeutics Market: Primary User Business Analysis

  • 6.1. Primary User Market Share, 2024 & 2033
  • 6.2. Primary User Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by primary user, 2021 to 2033 (USD Million)
  • 6.4. Orthopedic Surgeons
    • 6.4.1. Orthopedic Surgeons Market, 2021 - 2033 (USD Million)
  • 6.5. Rheumatologists
    • 6.5.1. Rheumatologists Market, 2021 - 2033 (USD Million)
  • 6.6. Sports Medicine Specialists
    • 6.6.1. Sports Medicine Specialists Market, 2021 - 2033 (USD Million)
  • 6.7. Regenerative Medicine Specialists
    • 6.7.1. Regenerative Medicine Specialists Market, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Stryker
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Zimmer Biomet Holdings, Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Medtronic
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Anika Therapeutics, Inc.
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Bioventus
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Vericel Corporation
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Smith & Nephew
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Fidia Farmaceutici S.p.A.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Seikagaku Corporation
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Sanofi
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 US osteoarthritis therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 4 US osteoarthritis therapeutics market, by application, 2021 - 2033 (USD Million)
  • Table 5 US osteoarthritis therapeutics market, by primary user, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 U.S. Osteoarthritis therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 U.S. Osteoarthritis therapeutics market dynamics
  • Fig. 12 U.S. Osteoarthritis therapeutics market: Porter's five forces analysis
  • Fig. 13 U.S. Osteoarthritis therapeutics market: PESTLE analysis
  • Fig. 14 Product market, 2021 - 2033 (USD Million)
  • Fig. 15 Viscosupplements market, 2021 - 2033 (USD Million)
  • Fig. 16 Platelet-Rich Plasma (PRP) Therapy market, 2021 - 2033 (USD Million)
  • Fig. 17 Bone Graft Substitutes market, 2021 - 2033 (USD Million)
  • Fig. 18 BMAC (Bone Marrow Aspirate Concentrate) Therapy market, 2021 - 2033 (USD Million)
  • Fig. 19 Adipose Tissue Therapy market, 2021 - 2033 (USD Million)
  • Fig. 20 Autologous Chondrocyte Implantation (ACI), Including MACI market, 2021 - 2033 (USD Million)
  • Fig. 21 Stem Cell (other) Substitutes market, 2021 - 2033 (USD Million)
  • Fig. 22 Others market, 2021 - 2033 (USD Million)
  • Fig. 23 Application market, 2021 - 2033 (USD Million)
  • Fig. 24 Knee Osteoarthritis market, 2021 - 2033 (USD Million)
  • Fig. 25 Hip Osteoarthritis market, 2021 - 2033 (USD Million)
  • Fig. 26 Shoulder Osteoarthritis market, 2021 - 2033 (USD Million)
  • Fig. 27 Spine Osteoarthritis market, 2021 - 2033 (USD Million)
  • Fig. 28 Ankle & Foot Osteoarthritis market, 2021 - 2033 (USD Million)
  • Fig. 29 Others market, 2021 - 2033 (USD Million)
  • Fig. 30 Primary User market, 2021 - 2033 (USD Million)
  • Fig. 31 Orthopedic Surgeons market, 2021 - 2033 (USD Million)
  • Fig. 32 Rheumatologists market, 2021 - 2033 (USD Million)
  • Fig. 33 Sports Medicine Specialists market, 2021 - 2033 (USD Million)
  • Fig. 34 Regenerative Medicine Specialists market, 2021 - 2033 (USD Million)
  • Fig. 35 Others market, 2021 - 2033 (USD Million)